Fig. 2From: Real-world effectiveness of fremanezumab in migraine patients initiating treatment in the United States: results from a retrospective chart studyEffectiveness outcomes by change from baseline in MMD: A) total population; B) dosing schedule subgroups; C) prior treatment failures subgroups. BL, baseline; MMD, monthly migraine days; Q, quarterly; M, monthly. aNumber of patients with available assessment at each time pointBack to article page